A-Alpha Bio

United States - Seattle, Washington

• 26/07/2023
• Series A
• $22,400,000

At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.

Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications.

A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.

Related People

David YoungerCo Founder

United States - Seattle, Washington

A-Alpha Bio partners with pharmaceutical companies to discover and optimize high-impact therapeutics.

LinkedIn https://www.linkedin.com/in/david-a-younger/